ZBIO (Zenas BioPharma) Gross-Profit-to-Asset % : 5.17% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Zenas BioPharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Zenas BioPharma's annualized Gross Profit for the quarter that ended in Dec. 2024 was $20.00 Mil. Zenas BioPharma's average Total Assets over the quarter that ended in Dec. 2024 was $386.70 Mil. Therefore, Zenas BioPharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 5.17%.

Zenas BioPharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Zenas BioPharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenas BioPharma Gross-Profit-to-Asset % Chart

Zenas BioPharma Annual Data

Trend

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

70.05

2.28

Zenas BioPharma Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial				-	-	-	-	5.17

Competitive Comparison of Zenas BioPharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Zenas BioPharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Zenas BioPharma Gross-Profit-to-Asset % Calculation

Zenas BioPharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	5	/	( (68.18	+	369.968)	/ 2 )
	=	5	/	219.074
	=	2.28 %

Zenas BioPharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	20	/	( (403.432	+	369.968)	/ 2 )
	=	20	/	386.7
	=	5.17 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Zenas BioPharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Zenas BioPharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenas BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenas BioPharma Inc (NAS:ZBIO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

852 Winter Street, Suite 250, Waltham, MA, USA, 02451

Website

https://www.zenasbio.com

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.